Evaluation of albumin use in a community hospital setting: A retrospective study looking at appropriate use and prescribing patterns.

PURPOSE: Albumin has been shown to be safe and effective in clinical practice for a wide variety of indications. The purpose of this medication use evaluation is to quantify the use of albumin in the community hospital setting based on indication and prescribing department. METHODS: This study is a retrospective, single-center, chart review over a 6-month period of 186 patients aged 18 and older who were treated with IV human albumin 5% or 25% at a single 202-bed community hospital setting from February 1, 2020, to August 1, 2020. A chart review was completed for each patient and the data collected included date of albumin administration, the ordering provider, the specialty of the provider, the indication for albumin as stated in the order, patient notes, crystalloid therapy use prior to albumin, albumin strength, the presence of acute or chronic renal, hepatic or respiratory disorders, and lab values denoting renal and hepatic function. Appropriate albumin use was determined utilizing criteria which included FDA labeled indications, the Surviving Sepsis Campaign, and existing literature. RESULTS: A total of 186 patients received albumin 5% or 25% IV solution at least once during the study period. The study population was 52.2% female, and the average age was 68 years. Of the patients selected for the study, 23 (11.6%) had chronic hepatic disease, and 37 (18.7%) had chronic renal disease. The top indications for which albumin was administered were sepsis or septic shock (25.3%), hypotension or hypovolemia (19.4%), intra-dialytic hypotension (13.4%), fluid support in surgery (10.8%), and nephrosis or nephropathy (10.8%). The departments with highest albumin use during this study period were critical care (41%), nephrology (28%), and surgery (17%). Overall, albumin was used for an appropriate indication in 126 out of 186 patients (67.7%). CONCLUSION: We found that albumin was most utilized for sepsis and septic shock, hypovolemia and hypotension, and intradialytic hypotension in our community hospital setting and it was most frequently ordered by critical care, nephrology, and surgical departments. Further research could determine if this trend is seen in other community hospital settings.

Acute Respiratory Failure due to Neuromyelitis Optica Treated Successfully with Plasmapheresis.

Neuromyelitis Optica (NMO) is a demyelinating autoimmune disease involving the central nervous system. Acute respiratory failure from cervical myelitis due to NMO is known to occur but is uncommon in monophasic disease and is treated with high dose steroids. We report a case of a patient with NMO who developed acute respiratory failure related to cervical spinal cord involvement, refractory to pulse dose steroid therapy, which resolved with plasmapheresis.

The effect of the endothelin-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17-week, double-blind, placebo-controlled crossover pilot study.

OBJECTIVE: To determine the effect of bosentan on subjects with poorly controlled asthma. METHODS: This was a double-blind, placebo-controlled crossover pilot study. Subjects were poorly controlled on anti-inflammatory and long acting ß-agonist therapy, and had a baseline forced expiratory volume in 1 second (FEV1) percent of predicted of 40 -70%. Subjects were randomized to receive either bosentan or placebo at the therapeutic dose of 125 mg twice a day for 4 weeks, and then crossed over to the alternate therapy. The asthma control test, asthma symptom scores, rescue albuterol use, and FEV1 were measured at baseline and during the last week of bosentan and placebo. Acute changes in FEV1 were measured after the initial therapeutic bosentan and placebo dose. RESULTS: Seven of eleven randomized subjects completed the protocol. There was no difference in change in FEV1 after the bosentan phase when compared with placebo (+0.08 ± 0.31 L and +0.23 ± 0.26 L p = .34). Changes from baseline values in the asthma control test and asthma symptom scores were also similar in bosentan and placebo phases (+1.71 ± 3.99 and +4.57 ± 4.39 p = .16) and (+0.14 ± 9.3 and -0.29 ± 5.28 p = .93). Rescue ß-agonist use did not change significantly during the last week of the bosentan phase when compared with placebo phase (-5.86 ± 0.94 puffs and -5.14 ± 16.85 puffs p = .94). Additionally, there was no difference in the change in FEV1 4 hours after bosentan 125 mg and placebo (-0.08 L ± 0.07 vs. +0.04 L ± 0.20 p = .20). CONCLUSIONS: In this pilot study, 4 weeks of bosentan did not improve FEV1, ß-agonist use, asthma symptom score, or asthma control test score in patients with poorly controlled asthma when compared with placebo.

Office-based ambulatory anesthesia: Factors that influence patient satisfaction or dissatisfaction with deep sedation/general anesthesia.

PURPOSE: The purpose of this report was to analyze data collected in an outcomes study in an attempt to identify factors that may be significant predictors of either patient satisfaction or dissatisfaction with deep sedation/general anesthesia (DS/GA) administered in an office-based setting. MATERIALS AND METHODS: To address the research purpose, we used a prospective cohort study design and sample of patients undergoing procedures in the office-based ambulatory setting of oral and maxillofacial surgeons practicing in the United States who received local anesthesia (LA), conscious sedation (CS), or DS/GA. The predictor variables were categorized as demographic, anesthetic technique, adverse events, and patient-oriented outcomes (satisfaction/dissatisfaction). Appropriate descriptive and exact P values were completed as indicated. Statistical significance was set at P < .05. Multivariate analyses were performed to support the interpretation of univariate findings. RESULTS: The sample was composed of 34,191 patients, of whom 71.9% patients received DS/GA. There were 20,455 patient satisfaction forms completed, of which 14,912 forms were from patients undergoing DS/GA. Of patients who received DS/GA, 95.8% were extremely or moderately satisfied, 3.1% were neutral, and 1.1% moderately or extremely dissatisfied. Increased age and memory of postoperative instructions were identified as factors, which predicted satisfaction. The addition of nitrous oxide to some regimens also appeared to increase satisfaction. Young age, anxiety, pain, vomiting, and being awake during the procedure were predictors of dissatisfaction. CONCLUSIONS: The findings of this study indicate that patients are overwhelmingly satisfied with DS/GA provided in an office-based ambulatory setting. Items identified as significant predictors of dissatisfaction (anxiety, pain, vomiting, being awake) generally confirm preexistent suppositions. Surprisingly, patient age (<10 years old) and memory of postoperative instructions appear to have relevance to dissatisfaction as well. Lack of specific regimens and controls prevents confirmation that nitrous oxide improves patient satisfaction rates. Although statistically significant, the variations, which resulted in a higher or lower satisfaction rate, are of questionable clinical significance in many cases.